These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12433824)

  • 1. Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.
    Shih PS; Huang JD
    Drug Metab Dispos; 2002 Dec; 30(12):1491-6. PubMed ID: 12433824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.
    Yu KS; Cho JY; Jang IJ; Hong KS; Chung JY; Kim JR; Lim HS; Oh DS; Yi SY; Liu KH; Shin JG; Shin SG
    Clin Pharmacol Ther; 2004 Aug; 76(2):104-12. PubMed ID: 15289787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.
    Eap CB; Buclin T; Hustert E; Bleiber G; Golay KP; Aubert AC; Baumann P; Telenti A; Kerb R
    Eur J Clin Pharmacol; 2004 Jun; 60(4):231-6. PubMed ID: 15114431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
    Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
    Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
    Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
    Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
    Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
    Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
    Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
    Swaisland HC; Cantarini MV; Fuhr R; Holt A
    Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
    Seng KY; Hee KH; Soon GH; Sapari NS; Soong R; Goh BC; Lee LS
    J Clin Pharmacol; 2014 Feb; 54(2):215-24. PubMed ID: 24214410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
    Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
    Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of quercetin on CYP3A activity in Chinese healthy participants.
    Duan KM; Wang SY; Ouyang W; Mao YM; Yang LJ
    J Clin Pharmacol; 2012 Jun; 52(6):940-6. PubMed ID: 21680781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
    Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
    Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
    Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
    J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.
    Zhang JJ; Zhang H; Ding XL; Ma S; Miao LY
    Eur J Clin Pharmacol; 2013 Apr; 69(4):807-12. PubMed ID: 23097010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals.
    Lee SJ; Lee SS; Jeong HE; Shon JH; Ryu JY; Sunwoo YE; Liu KH; Kang W; Park YJ; Shin CM; Shin JG
    Drug Metab Dispos; 2007 Nov; 35(11):2095-101. PubMed ID: 17724065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography.
    Eeckhoudt SL; Desager JP; Horsmans Y; De Winne AJ; Verbeeck RK
    J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):165-71. PubMed ID: 9686884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects.
    Min DI; Ellingrod VL; Marsh S; McLeod H
    Ther Drug Monit; 2004 Oct; 26(5):524-8. PubMed ID: 15385835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
    Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
    Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
    Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.